Changmao Biochemical Engineering Balance Sheet Health
Financial Health criteria checks 1/6
Changmao Biochemical Engineering has a total shareholder equity of CN¥633.0M and total debt of CN¥532.7M, which brings its debt-to-equity ratio to 84.2%. Its total assets and total liabilities are CN¥1.3B and CN¥635.7M respectively.
Key information
84.2%
Debt to equity ratio
CN¥532.73m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥71.97m |
| Equity | CN¥633.01m |
| Total liabilities | CN¥635.71m |
| Total assets | CN¥1.27b |
Recent financial health updates
No updates
Recent updates
Further Upside For Changmao Biochemical Engineering Company Limited (HKG:954) Shares Could Introduce Price Risks After 25% Bounce
Sep 23
Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist
Aug 02Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled
Nov 18We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability
Apr 28Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns
Aug 03Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital
May 04Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield
Feb 23Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?
Jan 26
A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary
Dec 02Financial Position Analysis
Short Term Liabilities: 954's short term assets (CN¥318.3M) do not cover its short term liabilities (CN¥367.5M).
Long Term Liabilities: 954's short term assets (CN¥318.3M) exceed its long term liabilities (CN¥268.2M).
Debt to Equity History and Analysis
Debt Level: 954's net debt to equity ratio (72.8%) is considered high.
Reducing Debt: 954's debt to equity ratio has increased from 0.08% to 84.2% over the past 5 years.
Debt Coverage: 954's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 954's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 23:51 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Changmao Biochemical Engineering Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|